MedinCell S.A. (MDCLF)
USD 6.98
(0.0%)
USD 6.98
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -25.03 Million EUR | 21.78% |
| 2023 | -32.01 Million EUR | -29.04% |
| 2022 | -24.8 Million EUR | -30.42% |
| 2021 | -19.02 Million EUR | 20.47% |
| 2020 | -23.91 Million EUR | -21.48% |
| 2019 | -19.68 Million EUR | -105.69% |
| 2018 | -9.57 Million EUR | -168.77% |
| 2017 | -3.56 Million EUR | -672.51% |
| 2016 | 622 Thousand EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -8.15 Million EUR | -100.0% |
| 2024 Q1 | -4.07 Million EUR | 77.67% |
| 2024 Q3 | -8.44 Million EUR | -3.46% |
| 2024 FY | -25.03 Million EUR | 21.78% |
| 2024 Q4 | -8.44 Million EUR | 0.0% |
| 2023 Q2 | -13.74 Million EUR | -100.0% |
| 2023 Q4 | -18.26 Million EUR | -100.0% |
| 2023 Q1 | -6.87 Million EUR | 47.32% |
| 2023 FY | -32.01 Million EUR | -29.04% |
| 2023 Q3 | -9.13 Million EUR | 33.57% |
| 2022 Q1 | -5.87 Million EUR | 28.88% |
| 2022 FY | -24.8 Million EUR | -30.42% |
| 2022 Q4 | -13.04 Million EUR | -100.0% |
| 2022 Q3 | -6.52 Million EUR | 44.51% |
| 2022 Q2 | -11.75 Million EUR | -100.0% |
| 2021 Q1 | -5.37 Million EUR | 63.95% |
| 2021 Q4 | -8.26 Million EUR | -100.83% |
| 2021 Q3 | -4.11 Million EUR | 61.73% |
| 2021 Q2 | -10.75 Million EUR | -100.0% |
| 2021 FY | -19.02 Million EUR | 20.47% |
| 2020 FY | -23.91 Million EUR | -21.48% |
| 2020 Q2 | -8.99 Million EUR | -100.0% |
| 2020 Q3 | -7.45 Million EUR | 17.12% |
| 2020 Q4 | -14.91 Million EUR | -100.0% |
| 2020 Q1 | -4.49 Million EUR | 8.7% |
| 2019 Q3 | -4.92 Million EUR | -0.27% |
| 2019 FY | -19.68 Million EUR | -105.69% |
| 2019 Q2 | -4.91 Million EUR | 0.0% |
| 2019 Q1 | -4.91 Million EUR | -108.79% |
| 2019 Q4 | -4.92 Million EUR | 0.0% |
| 2018 Q3 | -2.35 Million EUR | 3.19% |
| 2018 Q4 | -2.35 Million EUR | 0.0% |
| 2018 FY | -9.57 Million EUR | -168.77% |
| 2018 Q1 | -2.43 Million EUR | 0.0% |
| 2018 Q2 | -2.43 Million EUR | 0.0% |
| 2017 FY | -3.56 Million EUR | -672.51% |
| 2016 FY | 622 Thousand EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 66.6% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -280.742% |
| SQZ Biotechnologies Company | -79.46 Million USD | 68.491% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 147.26% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 138.441% |
| Mesoblast Limited | -87.95 Million USD | 71.533% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -1275.315% |
| Genus plc | 7.9 Million USD | 416.937% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -129.881% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -574.836% |
| Marizyme, Inc. | -65.34 Million USD | 61.684% |
| ContraFect Corporation | -65.15 Million USD | 61.57% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -183.107% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -412.437% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -1349.415% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -765.65% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -210.657% |
| MultiCell Technologies, Inc. | -380.07 USD | -6587633.839% |
| Accustem Sciences Inc. | -3.74 Million USD | -568.318% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 51.563% |
| EV Biologics, Inc. | -1.26 Million USD | -1875.955% |
| Q BioMed Inc. | -2.05 Million USD | -1120.12% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -570.721% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -3859.159% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -951.632% |
| Biomind Labs Inc. | -1.21 Million USD | -1961.896% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | -137.372% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -216.813% |
| Skye Bioscience, Inc. | -37.64 Million USD | 33.489% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -1053.924% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -167087.5% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -258.565% |
| IMV Inc. | -36.48 Million USD | 31.376% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -57.755% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -330.409% |
| GB Sciences, Inc. | -1.36 Million USD | -1738.762% |
| Alpha Cognition Inc. | -13.77 Million USD | -81.796% |
| HST Global, Inc. | -146.21 Thousand USD | -17024.684% |
| CSL Limited | 2.64 Billion USD | 100.948% |
| Halberd Corporation | -79.67 Thousand USD | -31324.77% |
| Enzolytics Inc. | -2.17 Million USD | -1050.204% |
| Resverlogix Corp. | -3.61 Million USD | -593.573% |
| Affymax, Inc. | -14.42 Million USD | -73.586% |
| SYBLEU INC | -180.3 Thousand USD | -13786.547% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -689.485% |
| argenx SE | -295.05 Million USD | 91.514% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 60.003% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 25648.98% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -530.205% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -727.392% |
| AVAX Technologies, Inc. | -6.41 Million USD | -290.386% |
| Zenith Capital Corp. | -10.59 Million USD | -136.297% |
| Genscript Biotech Corporation | -95.47 Million USD | 73.776% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -107627.39% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -503.917% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -41325.79% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 58.078% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -707.217% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -2270.895% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -1184.495% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -555.617% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -1148.706% |
| BioStem Technologies, Inc. | -8.48 Million USD | -195.156% |
| ONE Bio Corp. | 8.67 Million USD | 388.569% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -5572.804% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1774.9% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -1326.853% |
| Agentix Corp. | -1.37 Million USD | -1721.991% |
| LadRx Corporation | 400.44 Thousand USD | 6352.575% |
| Cell Source, Inc. | -5.32 Million USD | -370.532% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -5926.297% |
| Regen BioPharma, Inc. | 1.02 Million USD | 2546.293% |
| Regen BioPharma, Inc. | 1.02 Million USD | 2546.293% |
| NovAccess Global Inc. | -4.76 Million USD | -424.995% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 461.581% |
| Itoco Inc. | -1.86 Million USD | -1239.65% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -463.597% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -1400.18% |
| Kadimastem Ltd | -3.3 Million USD | -657.03% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -9057.943% |
| CytoDyn Inc. | -49.84 Million USD | 49.764% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -31580.437% |
| Mobile Lads Corp. | -2.26 Million USD | -1006.265% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -10875.465% |
| Qrons Inc. | -789.34 Thousand USD | -3071.989% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -2559.291% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -1099.321% |
| Rebus Holdings, Inc. | -1.02 Million USD | -2354.706% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -1452.516% |
| International Stem Cell Corporation | -131 Thousand USD | -19012.977% |
| Bioxytran, Inc. | -4.28 Million USD | -485.0% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -46034.287% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -889.548% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 47.916% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -1084.39% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -3106.354% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -690.341% |
| Neutra Corp. | -233.46 Thousand USD | -10624.52% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -23.395% |
| PureTech Health plc | -65.69 Million USD | 61.889% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -17.734% |
| IXICO plc | -1.17 Million USD | -2025.467% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -152.221% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 56.172% |
| CSL Limited | 2.64 Billion USD | 100.948% |
| Cellectis S.A. | -103.17 Million USD | 75.732% |